Secondary genomic alterations in non-Hodgkin's lymphomas: Tumor-specific profiles with impact on clinical behavior

Haematologica

Volumn 93, Issue 5, 2008, Pages 641-645

  Beà, Sílvia ^a   Campo, Elías ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

B CELL LYMPHOMA; BURKITT LYMPHOMA; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOME TRANSLOCATION; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE COURSE; EDITORIAL; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENOMICS; HUMAN; NONHODGKIN LYMPHOMA; PHENOTYPE;

B-LYMPHOCYTES; CELL PROLIFERATION; CLUSTER ANALYSIS; DISEASE PROGRESSION; GENOME; HUMANS; IMMUNE SYSTEM; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MODELS, BIOLOGICAL; MODELS, GENETIC; NUCLEIC ACID HYBRIDIZATION; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 43449110766     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13030     Document Type: Editorial

References (24)

1. Ferreira B, Garcia JF, Suela J, Mollejo M, Camacho FI, Carro A, et al. Comparative genome profiling across subtypes of low-grade B cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica 2008;93:670-9.
2. Sander S, Bullinger L, Leupolt E, Benner A, Kienle D, Katzenberger T, et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlation. Haematologica 2008;93:680-7.
3. Dierlamm J, Penas E, Bentink S, Wessendorf S, Berger F, Hummel M, et al. Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. Haematologica 2008;688-96.
4. Zenz T, Dohner H, Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin. Haematol 2007;20:439-53.
5. Kienle D, Krober A, Katzenberger T, Ott G, Leupolt E, Barth TF, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003;102:3003-9.
6. Ruiz-Ballesteros E, Mollejo M, Mateo M, Algara P, Martinez P, Piris MA. MicroRNA losses in the frequently deleted region of 7q in SMZL. Leukemia 2007;21:2547-9.
7. Kimm LR, deLeeuw RJ, Savage KJ, Rosenwald A, Campo E, Delabie J, et al. Frequent occurrence of deletions in primary mediastinal B-cell lymphoma. Genes Chromosomes Cancer 2007;46:1090-7.
8. Camacho E, Hernandez L, Hernandez S, Tort F, Bellosillo B, Bea S, et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002;99:238-44.
9. Fang NY, Greiner TC, Weisenburger DD, Chan WC, Vose JM, Smith LM, et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci USA 2003; 100:5372-7.
10. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007;25:5448-57.
11. Ouillette P, Erba H, Kujawski L, Kaminski M, Shedden K, Malek SN. Integrated genomic profiling of chronic lymphocytic leukemia identifies subtypes of deletion 13q14. Cancer Res 2008;68:1012-21.
12. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, et al. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 2006;203:311-7.
13. Oscier D, Owen R, Johnson S. Splenic marginal zone lymphoma. Blood Rev 2005;19:39-51.
14. Young KH, Weisenburger DD, Dave BJ, Smith L, Sanger W, Iqbal J, et al. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood 2007;110:4396-405.
15. Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der HB, Steijaert MM, et al. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Br J Haematol 2007;136:615-23.
16. Viardot A, Moller P, Hogel J, Werner K, Mechtersheimer G, Ho AD, et al. Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. J Clin Oncol 2002; 20:4523-30.
17. Bea S, Ribas M, Hernandez JM, Bosch F, Pinyol M, Hernandez L, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999;93:4365-74.
18. Kohlhammer H, Schwaenen C, Wessendorf S, Holzmann K, Kestler HA, Kienle D, et al. Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. Blood 2004;104:795-801.
19. Rubio-Moscardo F, Climent J, Siebert R, Piris MA, Martin-Subero JI, Nielander I, et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005; 105:4445-54.
20. Salaverria I, Zettl A, Bea S, Moreno V, Valls J, Hartmann E, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216-22.
21. Bea S, Colomo L, Lopez-Guillermo A, Salaverria I, Puig X, Pinyol M, et al. Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004;22:3498-506.
22. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005;106:3183-90.
23. Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441:106-10.
24. Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright G, et al. Oncogenic CARD11 mutations in human diffuse large B-cell lymphoma. Science 2008 Mar 6; [Epub ahead of print].